Emerging drugs for major depressive disorder: An update

Expert Opinion on Emerging Drugs

Volumn 17, Issue 3, 2012, Pages 285-294

  Rizvi, Sakina J ^a,b   Kennedy, Sidney H ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Acetylcholine; Amino acid; Antidepressants; Cytokines; Depression; Development; Monoamine; Neuropeptides; Neurotrophic

Indexed keywords

1 [1 (4 CHLOROPHENYL)CYCLOBUTYL] 3 METHYLBUTANAMINE; 3 (3,4 DICHLOROPHENYL) 2 (METHOXYMETHYL) 8 AZABICYCLO[3.2.1]OCTANE; AGOMELATINE; AMIBEGRON; AMINO ACID; AMITIFADINE; ANTIDEPRESSANT AGENT; BCI 952; BMS 820836; BUSPIRONE; CUTAMESINE; DESVENLAFAXINE; DOPAMINE TRANSPORTER; DOV 102,677; EDIVOXETINE; FLUVOXAMINE; GEPIRONE; KETAMINE; LUAA24530; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MILNACIPRAN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NORADRENALIN TRANSPORTER; PRAMIPEXOLE; SELEGILINE; SEROTONIN TRANSPORTER; TASIMELTEON; TEDATIOXETINE; TRIPLE REUPTAKE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPRESSIN; VILAZODONE; VORTIOXETINE;

CIRCADIAN RHYTHM; DRUG EFFICACY; DRUG TARGETING; EDITORIAL; HUMAN; MAJOR DEPRESSION; MEDICAL RESEARCH; NERVE FIBER GROWTH; NEUROPROTECTION; NONHUMAN;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, MAJOR; DRUG DISCOVERY; HUMANS; TREATMENT OUTCOME;

EID: 84865595125     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2012.681301     Document Type: Editorial

References (43)

1. Boseley S. June 13 2011. Research into brain disorders under threat as drug firms pull out. In guardian.co.uk. Available from: http://www.guardian.co. uk/science/2011/jun/13/research-braindisorders-under-threat [Retrieved 2 February 2012]
2. Collins PY, Patel V, Joestl SS, et al. Grand challenges in global mental health. Nature 2011;475:27-30
3. Kennedy SH, Rizvi SJ. Emerging drugs for major depressive disorder. Exp Opin Emerging Drugs 2009;14:1-15
4. Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 2007;131:596-610 (Pubitemid 350017760)
5. Lucas G, Rymar VV, Sadikot AF, Debonnel G. Further evidence for an antidepressant potential of the selective sigma1 agonist SA 4503: electrophysiological, morphological and behavioural studies. Int J Neuropsychopharmacol 2008;11:485-95 (Pubitemid 351744813)
6. Tottori K, Miwa T, Uwahodo Y, et al. Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology 2001;41:976-88 (Pubitemid 34024993)
7. Nishimura T, Ishima T, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS One 2008;3:e2558
8. Villard V, Meunier J, Chevallier N, Maurice T. Pharmacological interaction with the sigma1 (tau1)-receptor in the acute behavioral effects of antidepressants. J Pharmacol Sci 2011;115:279-92
9. Ishikawa M, Ishiwata K, Ishii K, et al. High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C] SA4503. Biol Psychiatry 2007;62:878-83 (Pubitemid 47488223)
10. Nakano M, Osada K, Misonoo A, et al. Fluvoxamine and sigma-1 receptor agonists dehydroepiandrosterone (DHEA)-sulfate induces the Ser473- phosphorylation of Akt-1 in PC12 cells. Life Sci 2010;86:309-14
11. Urani A, Roman FJ, Phan VL, et al. The antidepressant-like effect induced by sigma(1)-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J Pharmacol Exp Ther 2001;298:1269-79 (Pubitemid 32761949)
12. De Wied D, Diamant M, Fodor M. Central nervous system effects of the neurohypophyseal hormones and related peptides. Front Neuroendocrinol 1993;14:251-302 (Pubitemid 23321822)
13. van Londen L, Goekoop JG, van Kempen GM, et al. Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacol 1997;17:284-92 (Pubitemid 27440650)
14. van Londen L, Kerkhof GA, van den Berg F, et al. Plasma arginine vasopressin and motor activity in major depression. Biol Psychiatry 1998;43:196-204 (Pubitemid 28096557)
15. Racagni G, Riva MA, Molteni R, et al. Mode of action of agomelatine: synergy between melatonergic and 5-HT(2C) receptors. World J Biol Psychiatry 2011;12:574-87
16. Guiard BP, El Mansari M, Blier P. Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors. Curr Drug Targets 2009;10:1069-84
17. Providing Clinical Evidence of Effectiveness for Human Drugs and Biological Products. Guidance for Industry. Food and Drug Administration, 1998. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/UCM078749.pdf [Last accessed 6 February 2012]
18. First MB. DSM-5 proposals for mood disorders: a cost-benefit analysis. Curr Opin Psychiatry 2011;24:1-9
19. Laughren TP, Gobburu J, Temple RJ, et al. Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant. J Clin Psychiatry 2011;72:1166-73
20. Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol 2011;http://dx.doi.org/10.1016/j.euroneuro.2011.11.008 [Epub ahead of print]
21. Alvarez E, Perez V, Dragheim M, et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol 2011;DOI: 10.1017/ S1461145711001027 [Epub ahead of print]
22. Aan het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010;67:139-45
23. Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010;67:793-802
24. A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects with Major Depressive Disorder. GlaxoSmithKline, 2010. Available from: http://www.gsk-clinicalstudyregister.com/result-comp-list.jsp?compound= orvepitant&studyType=All&phase= All&population=All&marketing=All [Last accessed 23 January 2012]
25. Dauden E, Griffiths CE, Ortonne JP, et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol 2009;23:1374-82
26. Kekow J, Moots R, Khandker R, et al. Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis. Rheumatology (Oxford) 2011;50:401-9
27. Drevets WC, Furey ML. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry 2010;67:432-8
28. Furey ML, Khanna A, Hoffman EM, Drevets WC. Scopolamine produces larger antidepressant and antianxiety effects in women than in men. Neuropsychopharmacology 2010;35:2479-88
29. Nichols AI, Focht K, Jiang Q, et al. Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study. Clin Drug Investig 2011;31:155-67
30. Fabre LF, Brown CS, Smith LC, Derogatis LR. Gepirone-ER treatment of hypoactive sexual desire disorder (HSDD) associated with depression in women. J Sex Med 2011;8:1411-19
31. Fabre LF, Smith LC, DeRogatis LR. Gepirone-ER treatment of low sexual desire associated with depression in women as measured by the DeRogatis Inventory of Sexual Function (DISF) fantasy/cognition (desire) domain-a post hoc analysis. J Sex Med 2011;8:2569-81
32. Fabre LF, Clayton AH, Smith LC, et al. The effect of gepirone-er in the treatment of sexual dysfunction in depressed men. J Sex Med 2012;9:821-9
33. Tran P, Skolnick P, Czobor P, et al. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res 2012;46:64-71
34. Learned S, Graff O, Roychowdhury S, et al. Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo-and active-controlled clinical trials. J Psychopharmacol 2011;doi: 10.1177/0269881111424931 [Epub ahead of print]
35. Dube S, Dellva MA, Jones M, et al. A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression. J Psychiatr Res 2010;44:356-63
36. Pangallo B, Dellva MA, D'Souza DN, et al. A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder. J Psychiatr Res 2011;45:748-55
37. Gandey A. Pramipexole lawsuits a wake-up call for prescribers. 2010.Available from: www.medscape. com/viewarticle/734153 [Last accessed 23 January 2012]
38. Coric V, Feldman HH, Oren DA, et al. Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress Anxiety 2010;27:417-25
39. Blasey CM, Block TS, Belanoff JK, Roe RL. Efficacy and safety of mifepristone for the treatment of psychotic depression. J Clin Psychopharmacol 2011;31:436-40
40. Mathew SJ, Vythilingam M, Murrough JW, et al. A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. Eur Neuropsychopharmacol 2011;21:221-9
41. Wade AG, Crawford GM, Nemeroff CB, et al. Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response. Psychol Med 2011;41:2089-97
42. Binneman B, Feltner D, Kolluri S, et al. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry 2008;165:617-20 (Pubitemid 351705339)
43. Keller M, Montgomery S, Ball W, et al. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry 2006;59:216-23 (Pubitemid 43208967)